董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jim Tananbaum | 男 | President, Chief Executive Officer and Director | 57 | 未披露 | 未持股 | 2021-02-18 |
| Michael Rome | 男 | Vice President and Director | 36 | 未披露 | 未持股 | 2021-02-18 |
| Daniel Dubin | 男 | Director | 55 | 未披露 | 未持股 | 2021-02-18 |
| Deepa Pakianathan | 女 | Director | 56 | 未披露 | 未持股 | 2021-02-18 |
| Alisa Mall | 女 | Director | 43 | 未披露 | 未持股 | 2021-02-18 |
| Owen Hughes | 男 | Director | 46 | 未披露 | 未持股 | 2021-02-18 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jim Tananbaum | 男 | President, Chief Executive Officer and Director | 57 | 未披露 | 未持股 | 2021-02-18 |
| Dennis Ryan | 男 | Chief Financial Officer | 65 | 未披露 | 未持股 | 2021-02-18 |
| Michael Rome | 男 | Vice President and Director | 36 | 未披露 | 未持股 | 2021-02-18 |
董事简历
中英对照 | 中文 | 英文- Jim Tananbaum
-
Jim Tananbaum自2020年8月以来一直担任我们的总裁，首席执行官和董事。Tananbaum博士还是Foresite Capital的首席执行官，该公司是一家专注于美国的梦百合投资公司，由他于2011年创立。Tananbaum博士还担任Gemini Therapeutics，Inc.的董事。纳斯达克股票代码:GMNI（前身为Fs DevelopmentCorp.，由Foresite Capital的关联公司赞助的空白支票公司），自2020年6月起生效。在创立Foresite Capital之前，Tananbaum博士从2000年到2010年担任Prospect Venture Partners L.P.II和III，梦百合Venture Partnerships的联合创始人兼董事总经理。Tananbaum博士还是Geltex，Inc.（一家肠道药物制药公司，于1991年被Sanofi-Genzyme收购）和Theravance，Inc.（现为TheravanceBiopharma，Inc.，一家多元化的生物制药公司，专注于器官选择性药物，Innoviva，Inc.，一家专注于呼吸的梦百合资产管理公司，与葛兰素集团有限公司合作）的创始人。Tananbaum博士在耶鲁大学（Yale University）获得应用数学和计算机科学的B.S.和B.S.E.E.，并在哈佛大学（Harvard University）获得硕士学位和工商管理硕士学位。
Jim Tananbaum has been a director since June 2020. Prior to the closing of the merger between FS Development Corp. “FSDC” and Gemini Therapeutics Inc., Dr. Tananbaum also served as the President and Chief Executive Officer of FSDC since June 2020. Dr. Tananbaum is also the chief executive officer of Foresite Capital, a U.S.-focused healthcare investment firm, which he founded in 2011. Prior to founding Foresite Capital, Dr. Tananbaum served as Co-Founder and Managing Director of Prospect Venture Partners L.P. II and III, healthcare venture partnerships, from 2000 to 2010. Dr. Tananbaum was also the Founder of GelTex, Inc. in 1991 an intestinal medicine pharmaceutical company acquired by Sanofi-Genzyme, and Theravance, Inc. in 1997 (now Theravance Biopharma, Inc., a diversified biopharmaceutical company focused on organ-selective medicines, and Innoviva, Inc., a respiratory-focused healthcare asset management company partnered with Glaxo Group Limited). Dr. Tananbaum received a B.S. and a B.S.E.E. from Yale University in Applied Math and Computer Science, and an M.D. and an M.B.A. from Harvard University. - Jim Tananbaum自2020年8月以来一直担任我们的总裁，首席执行官和董事。Tananbaum博士还是Foresite Capital的首席执行官，该公司是一家专注于美国的梦百合投资公司，由他于2011年创立。Tananbaum博士还担任Gemini Therapeutics，Inc.的董事。纳斯达克股票代码:GMNI（前身为Fs DevelopmentCorp.，由Foresite Capital的关联公司赞助的空白支票公司），自2020年6月起生效。在创立Foresite Capital之前，Tananbaum博士从2000年到2010年担任Prospect Venture Partners L.P.II和III，梦百合Venture Partnerships的联合创始人兼董事总经理。Tananbaum博士还是Geltex，Inc.（一家肠道药物制药公司，于1991年被Sanofi-Genzyme收购）和Theravance，Inc.（现为TheravanceBiopharma，Inc.，一家多元化的生物制药公司，专注于器官选择性药物，Innoviva，Inc.，一家专注于呼吸的梦百合资产管理公司，与葛兰素集团有限公司合作）的创始人。Tananbaum博士在耶鲁大学（Yale University）获得应用数学和计算机科学的B.S.和B.S.E.E.，并在哈佛大学（Harvard University）获得硕士学位和工商管理硕士学位。
- Jim Tananbaum has been a director since June 2020. Prior to the closing of the merger between FS Development Corp. “FSDC” and Gemini Therapeutics Inc., Dr. Tananbaum also served as the President and Chief Executive Officer of FSDC since June 2020. Dr. Tananbaum is also the chief executive officer of Foresite Capital, a U.S.-focused healthcare investment firm, which he founded in 2011. Prior to founding Foresite Capital, Dr. Tananbaum served as Co-Founder and Managing Director of Prospect Venture Partners L.P. II and III, healthcare venture partnerships, from 2000 to 2010. Dr. Tananbaum was also the Founder of GelTex, Inc. in 1991 an intestinal medicine pharmaceutical company acquired by Sanofi-Genzyme, and Theravance, Inc. in 1997 (now Theravance Biopharma, Inc., a diversified biopharmaceutical company focused on organ-selective medicines, and Innoviva, Inc., a respiratory-focused healthcare asset management company partnered with Glaxo Group Limited). Dr. Tananbaum received a B.S. and a B.S.E.E. from Yale University in Applied Math and Computer Science, and an M.D. and an M.B.A. from Harvard University.
- Michael Rome
-
Michael Rome自2020年8月以来一直担任我们的Vice President和董事。他还担任Foresite Capital的董事总经理，在那里他曾担任多种职务（2016年以来）。他曾担任Fs DevelopmentCorp.（现为Gemini Therapeutics，Inc.，NASDAQ:GMNI）的Vice President和董事（从2020年6月到2021年2月与Gemini合并）。2015年9月至2016年7月，他是梦百合对冲基金Dafna Capital Management的分析师，在那里他覆盖并制定了中小型生物技术公司的投资理念。在加入Dafna Capital Management之前，Rome博士于2014年4月至2015年9月担任Vault Pharma（加州大学洛杉矶分校加州纳米系统研究所的学术初创公司）的高级科学家，从事早期药物开发。在过去的五年中，Rome博士在Turning PointTherapeutics，Inc.担任董事会观察员，该公司是一家临床阶段的精密肿瘤公司。Rome博士在加州大学洛杉矶分校（UCLA）获得分子、细胞和发育生物学学士学位，并在加州理工学院（Caltech）获得生物化学博士学位。
Michael Rome has served as a member of our board of directors since January 2021. Dr. Rome has served in various roles with Foresite Capital Management, an investment firm, since August 2016 including serving as Managing Director since May 2020. Prior to that, he served as an Analyst at DAFNA Capital Management LLC, a healthcare hedge fund, from September 2015 to July 2016. Dr. Rome also worked in early-stage drug development as a Senior Scientist for Vault Pharma, an academic start-up out of the California NanoSystems Institute at the University of California, Los Angeles from April 2014 to September 2015. Since December 2019 Dr. Rome has served on the board of directors of Kinnate Bioharma Inc. Nasdaq: KNTE, and since August 2020 has served on the board of directors of FS Development Corp. II (FSII). Dr. Rome currently serves on the board of directors of a privately held company, Remix Therapeutics Inc. Dr. Rome has also held board observer roles (past and present) at Turning Point Therapeutics, Inc. (Nasdaq: TPTX), Nurix Therapeutics, Inc. (Nasdaq: NRIX) and several privately held companies, including Maze Therapeutics, Inc. and PACT Pharma, Inc. Dr. Rome holds a Bachelor of Science in Molecular, Cellular and Developmental Biology from the University of California, Los Angeles and a Doctorate in Biochemistry, Biophysics and Molecular Biology from the California Institute of Technology. - Michael Rome自2020年8月以来一直担任我们的Vice President和董事。他还担任Foresite Capital的董事总经理，在那里他曾担任多种职务（2016年以来）。他曾担任Fs DevelopmentCorp.（现为Gemini Therapeutics，Inc.，NASDAQ:GMNI）的Vice President和董事（从2020年6月到2021年2月与Gemini合并）。2015年9月至2016年7月，他是梦百合对冲基金Dafna Capital Management的分析师，在那里他覆盖并制定了中小型生物技术公司的投资理念。在加入Dafna Capital Management之前，Rome博士于2014年4月至2015年9月担任Vault Pharma（加州大学洛杉矶分校加州纳米系统研究所的学术初创公司）的高级科学家，从事早期药物开发。在过去的五年中，Rome博士在Turning PointTherapeutics，Inc.担任董事会观察员，该公司是一家临床阶段的精密肿瘤公司。Rome博士在加州大学洛杉矶分校（UCLA）获得分子、细胞和发育生物学学士学位，并在加州理工学院（Caltech）获得生物化学博士学位。
- Michael Rome has served as a member of our board of directors since January 2021. Dr. Rome has served in various roles with Foresite Capital Management, an investment firm, since August 2016 including serving as Managing Director since May 2020. Prior to that, he served as an Analyst at DAFNA Capital Management LLC, a healthcare hedge fund, from September 2015 to July 2016. Dr. Rome also worked in early-stage drug development as a Senior Scientist for Vault Pharma, an academic start-up out of the California NanoSystems Institute at the University of California, Los Angeles from April 2014 to September 2015. Since December 2019 Dr. Rome has served on the board of directors of Kinnate Bioharma Inc. Nasdaq: KNTE, and since August 2020 has served on the board of directors of FS Development Corp. II (FSII). Dr. Rome currently serves on the board of directors of a privately held company, Remix Therapeutics Inc. Dr. Rome has also held board observer roles (past and present) at Turning Point Therapeutics, Inc. (Nasdaq: TPTX), Nurix Therapeutics, Inc. (Nasdaq: NRIX) and several privately held companies, including Maze Therapeutics, Inc. and PACT Pharma, Inc. Dr. Rome holds a Bachelor of Science in Molecular, Cellular and Developmental Biology from the University of California, Los Angeles and a Doctorate in Biochemistry, Biophysics and Molecular Biology from the California Institute of Technology.
- Daniel Dubin
-
Daniel Dubin自2006年1月起担任SVB Leerink（一家专门从事梦百合和生命科学的投资银行）的副董事长兼生物制药投资银行业务主管。他也是SVB Leerink’；的执行委员会成员。在1999年加入SVB Leerink之前，Dubin博士共同创立了MedaCorp，Inc.，这是一家为梦百合公司和投资者提供生物疗法和医疗设备商业潜力见解的供应商。Dubin博士拥有Dartmouth College化学学士学位和Harvard Medical School医学博士学位。
Daniel Dubin is also the Vice Chairman and Head of Biopharma Investment Banking at SVB Leerink, an investment bank specializing in healthcare and life sciences, a role he has held since January 2006. He also sits on SVB Leerink’s executive committee. Prior to joining SVB Leerink in 1999 Dr. Dubin co-founded MEDACorp, Inc., a provider of insights on the commercial potential of biotherapeutics and medical devices to healthcare companies and investors. Dr. Dubin holds a B.A. from Dartmouth College in Chemistry and an M.D. from Harvard Medical School. - Daniel Dubin自2006年1月起担任SVB Leerink（一家专门从事梦百合和生命科学的投资银行）的副董事长兼生物制药投资银行业务主管。他也是SVB Leerink’；的执行委员会成员。在1999年加入SVB Leerink之前，Dubin博士共同创立了MedaCorp，Inc.，这是一家为梦百合公司和投资者提供生物疗法和医疗设备商业潜力见解的供应商。Dubin博士拥有Dartmouth College化学学士学位和Harvard Medical School医学博士学位。
- Daniel Dubin is also the Vice Chairman and Head of Biopharma Investment Banking at SVB Leerink, an investment bank specializing in healthcare and life sciences, a role he has held since January 2006. He also sits on SVB Leerink’s executive committee. Prior to joining SVB Leerink in 1999 Dr. Dubin co-founded MEDACorp, Inc., a provider of insights on the commercial potential of biotherapeutics and medical devices to healthcare companies and investors. Dr. Dubin holds a B.A. from Dartmouth College in Chemistry and an M.D. from Harvard Medical School.
- Deepa Pakianathan
-
Deepa Pakianathan，自2001年起担任Delphi Ventures（一家风险投资公司）管理成员。自2019年9月起，她也是制药公司REDD Pharmaceuticals，Inc.的首席执行官。她目前在CalitheraBiosciences，Inc.的董事会任职。纳斯达克市场代码:CALA，Karyopharm Therapeutics，Inc.（纳斯达克市场代码:KPTI），Mereo BioPharma Group plc（原OncomedPharmaceuticals，Inc.）（纳斯达克市场代码:MREO）和TheravanceBiopharma，Inc.（纳斯达克市场代码:TBPH），并担任旧金山音乐学院董事会执行副主席兼财务主管。在过去的五年里，她还担任过Fs DevelopmentCorp.（现为Gemini Therapeutics，Inc.）、AlderBiopharmaceuticals，Inc.和AlexzaPharmaceuticals，Inc.的董事会成员。Dr.Pakianathan持有B.SC.来自印度孟买大学，获理学硕士学位。拥有印度孟买大学癌症研究所的硕士学位和维克森林大学的博士学位。
Deepa Pakianathan, Since 2001 Dr. Pakianathan has served as a Managing Member at Delphi Ventures, a venture capital firm. She is also the Chief Executive Officer of Redd Pharmaceuticals, Inc., a pharmaceuticals company, since September 2019. She currently serves on the boards of directors of Calithera Biosciences, Inc. Nasdaq: CALA, Karyopharm Therapeutics, Inc. (Nasdaq: KPTI), Mereo Biopharma Group plc (formerly OncoMed Pharmaceuticals, Inc.) (Nasdaq: MREO) and Theravance Biopharma, Inc. (Nasdaq: TBPH), and serves as the Executive Vice Chair and Treasurer on the Board of Trustees of the San Francisco Conservatory of Music. In the past five years, she also served on the board of directors of FS Development Corp. (now Gemini Therapeutics, Inc.), Alder Biopharmaceuticals, Inc. and Alexza Pharmaceuticals, Inc. Dr. Pakianathan holds a B.Sc. from the University of Bombay, India, an M.Sc. from The Cancer Research Institute at the University of Bombay, India and an M.S. and a Ph.D. from Wake Forest University. - Deepa Pakianathan，自2001年起担任Delphi Ventures（一家风险投资公司）管理成员。自2019年9月起，她也是制药公司REDD Pharmaceuticals，Inc.的首席执行官。她目前在CalitheraBiosciences，Inc.的董事会任职。纳斯达克市场代码:CALA，Karyopharm Therapeutics，Inc.（纳斯达克市场代码:KPTI），Mereo BioPharma Group plc（原OncomedPharmaceuticals，Inc.）（纳斯达克市场代码:MREO）和TheravanceBiopharma，Inc.（纳斯达克市场代码:TBPH），并担任旧金山音乐学院董事会执行副主席兼财务主管。在过去的五年里，她还担任过Fs DevelopmentCorp.（现为Gemini Therapeutics，Inc.）、AlderBiopharmaceuticals，Inc.和AlexzaPharmaceuticals，Inc.的董事会成员。Dr.Pakianathan持有B.SC.来自印度孟买大学，获理学硕士学位。拥有印度孟买大学癌症研究所的硕士学位和维克森林大学的博士学位。
- Deepa Pakianathan, Since 2001 Dr. Pakianathan has served as a Managing Member at Delphi Ventures, a venture capital firm. She is also the Chief Executive Officer of Redd Pharmaceuticals, Inc., a pharmaceuticals company, since September 2019. She currently serves on the boards of directors of Calithera Biosciences, Inc. Nasdaq: CALA, Karyopharm Therapeutics, Inc. (Nasdaq: KPTI), Mereo Biopharma Group plc (formerly OncoMed Pharmaceuticals, Inc.) (Nasdaq: MREO) and Theravance Biopharma, Inc. (Nasdaq: TBPH), and serves as the Executive Vice Chair and Treasurer on the Board of Trustees of the San Francisco Conservatory of Music. In the past five years, she also served on the board of directors of FS Development Corp. (now Gemini Therapeutics, Inc.), Alder Biopharmaceuticals, Inc. and Alexza Pharmaceuticals, Inc. Dr. Pakianathan holds a B.Sc. from the University of Bombay, India, an M.Sc. from The Cancer Research Institute at the University of Bombay, India and an M.S. and a Ph.D. from Wake Forest University.
- Alisa Mall
-
Alisa Mall，是Foresite Capital公司的董事总经理，负责公司发展、长期资本战略、投资者关系和环境、社会和治理参与。在加入Foresite Capital之前，Mall女士于2011年至2020年11月担任纽约卡耐基公司（Carnegie Corporation of New York）的投资董事总经理，该公司是一家支持教育，民主参与和国际和平创新的慈善基金会，并于2009年至2011年担任卡耐基公司的投资副总监。此前，她曾担任Tishman Speyer Properties公司（商业房地产公司）的股票资本市场主管（2007年至2009年），以及Orrick Herrington&Sutcliffe LLP（全球律师事务所）的律师（2004年至2007年）。Mall女士是JBG Smith NYSE:JBGS的董事会和治理委员会成员，这是一家房地产投资信托基金。她也任职于the Pension Real Estate Association（PREA）、Breakthrough New York和Bronfman Fellowship的董事会，是UJA-Federation of New York的投资委员会和Declaration Partners（家族办公室）的咨询委员会的成员。Mall女士在斯坦福法学院（Stanford Law School）获得法学博士学位，在耶鲁大学（Yale College）获得政治学学士学位。
Alisa Mall is Managing Director at Foresite Capital, responsible for corporate development, long-term capital strategy, investor relations and environmental, social and governance engagement. Prior to joining Foresite Capital, from 2011 to November 2020 Ms. Mall served as Managing Director of Investments at Carnegie Corporation of New York, a philanthropic foundation supporting innovations in education, democratic engagement and international peace, and as Associate Director of Investments for Carnegie Corporation from 2009 to 2011. Previously, she was Director, Equity Capital Markets at Tishman Speyer Properties, a commercial real estate company, from 2007 to 2009 and an attorney with global law firm Orrick Herrington & Sutcliffe LLP from 2004 to 2007. Ms. Mall is a member of the board of directors and governance committee of JBG Smith NYSE: JBGS, a real estate investment trust. She also serves on the boards of the Pension Real Estate Association (PREA), Breakthrough New York and the Bronfman Fellowship, and is a member of the investment committee of UJA-Federation of New York and the advisory board of Declaration Partners, a family office. Ms. Mall received a J.D. from Stanford Law School and a B.A. in Political Science from Yale College. - Alisa Mall，是Foresite Capital公司的董事总经理，负责公司发展、长期资本战略、投资者关系和环境、社会和治理参与。在加入Foresite Capital之前，Mall女士于2011年至2020年11月担任纽约卡耐基公司（Carnegie Corporation of New York）的投资董事总经理，该公司是一家支持教育，民主参与和国际和平创新的慈善基金会，并于2009年至2011年担任卡耐基公司的投资副总监。此前，她曾担任Tishman Speyer Properties公司（商业房地产公司）的股票资本市场主管（2007年至2009年），以及Orrick Herrington&Sutcliffe LLP（全球律师事务所）的律师（2004年至2007年）。Mall女士是JBG Smith NYSE:JBGS的董事会和治理委员会成员，这是一家房地产投资信托基金。她也任职于the Pension Real Estate Association（PREA）、Breakthrough New York和Bronfman Fellowship的董事会，是UJA-Federation of New York的投资委员会和Declaration Partners（家族办公室）的咨询委员会的成员。Mall女士在斯坦福法学院（Stanford Law School）获得法学博士学位，在耶鲁大学（Yale College）获得政治学学士学位。
- Alisa Mall is Managing Director at Foresite Capital, responsible for corporate development, long-term capital strategy, investor relations and environmental, social and governance engagement. Prior to joining Foresite Capital, from 2011 to November 2020 Ms. Mall served as Managing Director of Investments at Carnegie Corporation of New York, a philanthropic foundation supporting innovations in education, democratic engagement and international peace, and as Associate Director of Investments for Carnegie Corporation from 2009 to 2011. Previously, she was Director, Equity Capital Markets at Tishman Speyer Properties, a commercial real estate company, from 2007 to 2009 and an attorney with global law firm Orrick Herrington & Sutcliffe LLP from 2004 to 2007. Ms. Mall is a member of the board of directors and governance committee of JBG Smith NYSE: JBGS, a real estate investment trust. She also serves on the boards of the Pension Real Estate Association (PREA), Breakthrough New York and the Bronfman Fellowship, and is a member of the investment committee of UJA-Federation of New York and the advisory board of Declaration Partners, a family office. Ms. Mall received a J.D. from Stanford Law School and a B.A. in Political Science from Yale College.
- Owen Hughes
-
Owen Hughes，2013年4月起，他担任我公司董事会成员；2013年起，担任Intarcia Therapeutics, Inc.的首席商务官和公司发展主管；2008至2013年，担任贝恩资本（Bain Capital）旗下的对冲基金Brookside Capital的董事，管理上市与私营卫生保健投资；2006至2008年，担任Pyramis Global Advisors的高级投资组合经理；2003至2006年，共同成立了Triathlon Fund Management并担任合伙人 ；2001至2003年，担任齐夫兄弟投资（Ziff Brothers Investments）的投资助理；1998至2001年，担任摩根斯坦利（Morgan Stanley）和美林证券（Merrill Lynch）的助理副总裁。他在达特茅斯学院（Dartmouth College）获得文学士学位。
Owen Hughes is also President, Chief Executive Officer and director of Cullinan Oncology, LLC, an oncology therapeutics company, since September 2017. Prior to joining Cullinan Oncology, Mr. Hughes served as the Chief Business Officer and head of Corporate Development at Intarcia Therapeutics, Inc., a biopharmaceutical company, from February 2013 to September 2017. Mr. Hughes previously acted as Director at Brookside Capital Investors, L.P., a Bain Capital hedge fund, and Senior Portfolio Manager at Pyramis Global Advisors LLC, a Fidelity Investments company. He also serves as Chairman of Radius Health, Inc. Nasdaq: RDUS and as a director of Translate Bio, Inc. (Nasdaq: TBIO) and Wren Therapeutics, Inc. In the past five years, he also served on the board of directors of Malin Corporation plc. Mr. Hughes received a B.A. from Dartmouth College in History. - Owen Hughes，2013年4月起，他担任我公司董事会成员；2013年起，担任Intarcia Therapeutics, Inc.的首席商务官和公司发展主管；2008至2013年，担任贝恩资本（Bain Capital）旗下的对冲基金Brookside Capital的董事，管理上市与私营卫生保健投资；2006至2008年，担任Pyramis Global Advisors的高级投资组合经理；2003至2006年，共同成立了Triathlon Fund Management并担任合伙人 ；2001至2003年，担任齐夫兄弟投资（Ziff Brothers Investments）的投资助理；1998至2001年，担任摩根斯坦利（Morgan Stanley）和美林证券（Merrill Lynch）的助理副总裁。他在达特茅斯学院（Dartmouth College）获得文学士学位。
- Owen Hughes is also President, Chief Executive Officer and director of Cullinan Oncology, LLC, an oncology therapeutics company, since September 2017. Prior to joining Cullinan Oncology, Mr. Hughes served as the Chief Business Officer and head of Corporate Development at Intarcia Therapeutics, Inc., a biopharmaceutical company, from February 2013 to September 2017. Mr. Hughes previously acted as Director at Brookside Capital Investors, L.P., a Bain Capital hedge fund, and Senior Portfolio Manager at Pyramis Global Advisors LLC, a Fidelity Investments company. He also serves as Chairman of Radius Health, Inc. Nasdaq: RDUS and as a director of Translate Bio, Inc. (Nasdaq: TBIO) and Wren Therapeutics, Inc. In the past five years, he also served on the board of directors of Malin Corporation plc. Mr. Hughes received a B.A. from Dartmouth College in History.
高管简历
中英对照 | 中文 | 英文- Jim Tananbaum
Jim Tananbaum自2020年8月以来一直担任我们的总裁，首席执行官和董事。Tananbaum博士还是Foresite Capital的首席执行官，该公司是一家专注于美国的梦百合投资公司，由他于2011年创立。Tananbaum博士还担任Gemini Therapeutics，Inc.的董事。纳斯达克股票代码:GMNI（前身为Fs DevelopmentCorp.，由Foresite Capital的关联公司赞助的空白支票公司），自2020年6月起生效。在创立Foresite Capital之前，Tananbaum博士从2000年到2010年担任Prospect Venture Partners L.P.II和III，梦百合Venture Partnerships的联合创始人兼董事总经理。Tananbaum博士还是Geltex，Inc.（一家肠道药物制药公司，于1991年被Sanofi-Genzyme收购）和Theravance，Inc.（现为TheravanceBiopharma，Inc.，一家多元化的生物制药公司，专注于器官选择性药物，Innoviva，Inc.，一家专注于呼吸的梦百合资产管理公司，与葛兰素集团有限公司合作）的创始人。Tananbaum博士在耶鲁大学（Yale University）获得应用数学和计算机科学的B.S.和B.S.E.E.，并在哈佛大学（Harvard University）获得硕士学位和工商管理硕士学位。
Jim Tananbaum has been a director since June 2020. Prior to the closing of the merger between FS Development Corp. “FSDC” and Gemini Therapeutics Inc., Dr. Tananbaum also served as the President and Chief Executive Officer of FSDC since June 2020. Dr. Tananbaum is also the chief executive officer of Foresite Capital, a U.S.-focused healthcare investment firm, which he founded in 2011. Prior to founding Foresite Capital, Dr. Tananbaum served as Co-Founder and Managing Director of Prospect Venture Partners L.P. II and III, healthcare venture partnerships, from 2000 to 2010. Dr. Tananbaum was also the Founder of GelTex, Inc. in 1991 an intestinal medicine pharmaceutical company acquired by Sanofi-Genzyme, and Theravance, Inc. in 1997 (now Theravance Biopharma, Inc., a diversified biopharmaceutical company focused on organ-selective medicines, and Innoviva, Inc., a respiratory-focused healthcare asset management company partnered with Glaxo Group Limited). Dr. Tananbaum received a B.S. and a B.S.E.E. from Yale University in Applied Math and Computer Science, and an M.D. and an M.B.A. from Harvard University.- Jim Tananbaum自2020年8月以来一直担任我们的总裁，首席执行官和董事。Tananbaum博士还是Foresite Capital的首席执行官，该公司是一家专注于美国的梦百合投资公司，由他于2011年创立。Tananbaum博士还担任Gemini Therapeutics，Inc.的董事。纳斯达克股票代码:GMNI（前身为Fs DevelopmentCorp.，由Foresite Capital的关联公司赞助的空白支票公司），自2020年6月起生效。在创立Foresite Capital之前，Tananbaum博士从2000年到2010年担任Prospect Venture Partners L.P.II和III，梦百合Venture Partnerships的联合创始人兼董事总经理。Tananbaum博士还是Geltex，Inc.（一家肠道药物制药公司，于1991年被Sanofi-Genzyme收购）和Theravance，Inc.（现为TheravanceBiopharma，Inc.，一家多元化的生物制药公司，专注于器官选择性药物，Innoviva，Inc.，一家专注于呼吸的梦百合资产管理公司，与葛兰素集团有限公司合作）的创始人。Tananbaum博士在耶鲁大学（Yale University）获得应用数学和计算机科学的B.S.和B.S.E.E.，并在哈佛大学（Harvard University）获得硕士学位和工商管理硕士学位。
- Jim Tananbaum has been a director since June 2020. Prior to the closing of the merger between FS Development Corp. “FSDC” and Gemini Therapeutics Inc., Dr. Tananbaum also served as the President and Chief Executive Officer of FSDC since June 2020. Dr. Tananbaum is also the chief executive officer of Foresite Capital, a U.S.-focused healthcare investment firm, which he founded in 2011. Prior to founding Foresite Capital, Dr. Tananbaum served as Co-Founder and Managing Director of Prospect Venture Partners L.P. II and III, healthcare venture partnerships, from 2000 to 2010. Dr. Tananbaum was also the Founder of GelTex, Inc. in 1991 an intestinal medicine pharmaceutical company acquired by Sanofi-Genzyme, and Theravance, Inc. in 1997 (now Theravance Biopharma, Inc., a diversified biopharmaceutical company focused on organ-selective medicines, and Innoviva, Inc., a respiratory-focused healthcare asset management company partnered with Glaxo Group Limited). Dr. Tananbaum received a B.S. and a B.S.E.E. from Yale University in Applied Math and Computer Science, and an M.D. and an M.B.A. from Harvard University.
- Dennis Ryan
Dennis Ryan自2020年8月起担任我们的首席财务官。自2011年以来，Ryan先生还领导了Foresite Capital的运营集团，担任首席财务官兼董事总经理。他此前曾担任Fs DevelopmentCorp.（现为Gemini Therapeutics，Inc.，NASDAQ:GMNI）的首席财务官（从2020年6月到2021年2月与Gemini合并）。他目前担任Whistlestop公司（一个非营利组织，为老年人提供运输和营养服务）的董事会总裁。他在加州大学伯克利分校（University of California，Berkeley）获得经济学学士学位，在圣克拉拉大学（University of Santa Clara）获得工商管理硕士学位。Ryan先生是加州一名有执照的注册会计师。
Dennis Ryan has been our Chief Financial Officer since August 2020. Since 2011 Mr. Ryan has also led the Operations Group at Foresite Capital as Chief Financial Officer and Managing Director. He previously served as Chief Financial Officer of FS Development Corp. now Gemini Therapeutics, Inc., Nasdaq: GMNI from June 2020 to its merger with Gemini in February 2021. He currently serves as Board President of Whistlestop, a non-profit providing transportation and nutrition services to seniors. He received a B.A. from University of California, Berkeley in Economics, and an M.B.A from the University of Santa Clara. Mr. Ryan is a licensed certified public accountant in California.- Dennis Ryan自2020年8月起担任我们的首席财务官。自2011年以来，Ryan先生还领导了Foresite Capital的运营集团，担任首席财务官兼董事总经理。他此前曾担任Fs DevelopmentCorp.（现为Gemini Therapeutics，Inc.，NASDAQ:GMNI）的首席财务官（从2020年6月到2021年2月与Gemini合并）。他目前担任Whistlestop公司（一个非营利组织，为老年人提供运输和营养服务）的董事会总裁。他在加州大学伯克利分校（University of California，Berkeley）获得经济学学士学位，在圣克拉拉大学（University of Santa Clara）获得工商管理硕士学位。Ryan先生是加州一名有执照的注册会计师。
- Dennis Ryan has been our Chief Financial Officer since August 2020. Since 2011 Mr. Ryan has also led the Operations Group at Foresite Capital as Chief Financial Officer and Managing Director. He previously served as Chief Financial Officer of FS Development Corp. now Gemini Therapeutics, Inc., Nasdaq: GMNI from June 2020 to its merger with Gemini in February 2021. He currently serves as Board President of Whistlestop, a non-profit providing transportation and nutrition services to seniors. He received a B.A. from University of California, Berkeley in Economics, and an M.B.A from the University of Santa Clara. Mr. Ryan is a licensed certified public accountant in California.
- Michael Rome
Michael Rome自2020年8月以来一直担任我们的Vice President和董事。他还担任Foresite Capital的董事总经理，在那里他曾担任多种职务（2016年以来）。他曾担任Fs DevelopmentCorp.（现为Gemini Therapeutics，Inc.，NASDAQ:GMNI）的Vice President和董事（从2020年6月到2021年2月与Gemini合并）。2015年9月至2016年7月，他是梦百合对冲基金Dafna Capital Management的分析师，在那里他覆盖并制定了中小型生物技术公司的投资理念。在加入Dafna Capital Management之前，Rome博士于2014年4月至2015年9月担任Vault Pharma（加州大学洛杉矶分校加州纳米系统研究所的学术初创公司）的高级科学家，从事早期药物开发。在过去的五年中，Rome博士在Turning PointTherapeutics，Inc.担任董事会观察员，该公司是一家临床阶段的精密肿瘤公司。Rome博士在加州大学洛杉矶分校（UCLA）获得分子、细胞和发育生物学学士学位，并在加州理工学院（Caltech）获得生物化学博士学位。
Michael Rome has served as a member of our board of directors since January 2021. Dr. Rome has served in various roles with Foresite Capital Management, an investment firm, since August 2016 including serving as Managing Director since May 2020. Prior to that, he served as an Analyst at DAFNA Capital Management LLC, a healthcare hedge fund, from September 2015 to July 2016. Dr. Rome also worked in early-stage drug development as a Senior Scientist for Vault Pharma, an academic start-up out of the California NanoSystems Institute at the University of California, Los Angeles from April 2014 to September 2015. Since December 2019 Dr. Rome has served on the board of directors of Kinnate Bioharma Inc. Nasdaq: KNTE, and since August 2020 has served on the board of directors of FS Development Corp. II (FSII). Dr. Rome currently serves on the board of directors of a privately held company, Remix Therapeutics Inc. Dr. Rome has also held board observer roles (past and present) at Turning Point Therapeutics, Inc. (Nasdaq: TPTX), Nurix Therapeutics, Inc. (Nasdaq: NRIX) and several privately held companies, including Maze Therapeutics, Inc. and PACT Pharma, Inc. Dr. Rome holds a Bachelor of Science in Molecular, Cellular and Developmental Biology from the University of California, Los Angeles and a Doctorate in Biochemistry, Biophysics and Molecular Biology from the California Institute of Technology.- Michael Rome自2020年8月以来一直担任我们的Vice President和董事。他还担任Foresite Capital的董事总经理，在那里他曾担任多种职务（2016年以来）。他曾担任Fs DevelopmentCorp.（现为Gemini Therapeutics，Inc.，NASDAQ:GMNI）的Vice President和董事（从2020年6月到2021年2月与Gemini合并）。2015年9月至2016年7月，他是梦百合对冲基金Dafna Capital Management的分析师，在那里他覆盖并制定了中小型生物技术公司的投资理念。在加入Dafna Capital Management之前，Rome博士于2014年4月至2015年9月担任Vault Pharma（加州大学洛杉矶分校加州纳米系统研究所的学术初创公司）的高级科学家，从事早期药物开发。在过去的五年中，Rome博士在Turning PointTherapeutics，Inc.担任董事会观察员，该公司是一家临床阶段的精密肿瘤公司。Rome博士在加州大学洛杉矶分校（UCLA）获得分子、细胞和发育生物学学士学位，并在加州理工学院（Caltech）获得生物化学博士学位。
- Michael Rome has served as a member of our board of directors since January 2021. Dr. Rome has served in various roles with Foresite Capital Management, an investment firm, since August 2016 including serving as Managing Director since May 2020. Prior to that, he served as an Analyst at DAFNA Capital Management LLC, a healthcare hedge fund, from September 2015 to July 2016. Dr. Rome also worked in early-stage drug development as a Senior Scientist for Vault Pharma, an academic start-up out of the California NanoSystems Institute at the University of California, Los Angeles from April 2014 to September 2015. Since December 2019 Dr. Rome has served on the board of directors of Kinnate Bioharma Inc. Nasdaq: KNTE, and since August 2020 has served on the board of directors of FS Development Corp. II (FSII). Dr. Rome currently serves on the board of directors of a privately held company, Remix Therapeutics Inc. Dr. Rome has also held board observer roles (past and present) at Turning Point Therapeutics, Inc. (Nasdaq: TPTX), Nurix Therapeutics, Inc. (Nasdaq: NRIX) and several privately held companies, including Maze Therapeutics, Inc. and PACT Pharma, Inc. Dr. Rome holds a Bachelor of Science in Molecular, Cellular and Developmental Biology from the University of California, Los Angeles and a Doctorate in Biochemistry, Biophysics and Molecular Biology from the California Institute of Technology.